Smarter, informative biomarker testing

Join our mission to inform and improve treatment decisions.

First, select a disease state.

Lung Cancer

Non–Small Cell Lung Cancer

GI Cancer

Biliary Tract Cancer
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer

Go deeper by selecting a biomarker.

Beyond the Report

These interactive learning modules bridge the gap between biomarker test report findings and clinical decision-making.

HER2 + CLDN18.2 + Advanced Gastroesophageal Junction Cancer

KRAS G12D-Mutant Advanced Pancreatic Cancer

Advanced EGFR-Mutant Non-Small Cell Lung Cancer

AE Monitoring and Management Strategies for MET Inhibitors in NSCLC

Breakthrough therapies matter.

We advocate for biomarker status to guide targeted treatments.

Lifesaving diagnostics matter.

We invite everyone to the table, from innovators to associations.

Optimal outcomes matter.

We invite collaboration through live, community training events.

Featured Lung Cancer Content

OL2M58S

EGFR-Targeted Therapy Sequencing After Resistance in NSCLC

OL2M58S

Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response

OL2M58S

Access to Molecular Testing Across Institutions: Barriers, Resources, and Real-World Solutions

OL2M58S

Adapting to Tumor Evolution: Resistance Mechanisms and Sequencing After Progression

Featured GI Cancer Content

2:47

FGFR in Gastric Cancers: Advances in Biomarker Development and Targeted Therapy

2:23

TIGIT in Gastric Cancers: Emerging Insights in Biomarker and Drug Development

3:36

EBV in Gastric Cancers: Advances in Biomarker Development and Targeted Therapy

4:05

EGFR in Gastric Cancers: Therapeutic and Biomarker Advances

Biomarker Resources

External links to additional information for you and your patients.

Beyond the Report

Interactive video series designed to bridge the gap between biomarker test report findings and clinical decision- making.

Looking for Interactive Training?

Learn how to implement biomarker testing in your practice.

Our Mission

We bring stakeholders together for the shared purpose of providing accurate and relevant information to the broader oncology community about the importance of testing and biomarker identification, and how to utilize biomarker status to inform treatment decisions.

We invite you—health care professionals, pharmaceutical and biotech enterprises, associations, and advocacy groups—to engage with our resources and join the cause.

We champion—and demonstrate—the importance of biomarker testing, comprehensive genomic profiling, and identification of actionable targets across disease states.